Skip to main content
Lincoln Pharmaceuticals ltd. logo

Lincoln Pharmaceuticals ltd. — Investor Relations & Filings

Ticker · LINCOLN ISIN · INE405C01035 LEI · 3358004B6OBJNW8RTT10 BSE.NS Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2019-12-07 Capital/Financing Update
Country IN India
Listing BSE.NS LINCOLN

About Lincoln Pharmaceuticals ltd.

https://www.lincolnpharma.com/

Lincoln Pharmaceuticals Ltd. focuses on the development, manufacturing, and marketing of a diverse range of therapeutic formulations. The organization operates advanced manufacturing facilities certified by international standards, including WHO-GMP. Its portfolio spans multiple areas such as anti-infectives, cardiovascular, gastrointestinal, respiratory, and pain management. The company is recognized for its research and development initiatives, particularly in Novel Drug Delivery Systems (NDDS). Key offerings include specialized treatments for tinnitus and a wide array of formulations in dosage forms like tablets, capsules, liquid orals, and injectables. It maintains a significant global footprint, supplying products to numerous international markets across Africa, Southeast Asia, and Latin America, supported by a robust distribution network for its extensive healthcare catalog.

Recent filings

Filing Released Lang Actions
Scheme of Arrangement
Capital/Financing Update Classification · 95% confidence The document is dated December 7, 2019, and is titled as the outcome of a Board Meeting regarding the intimation of a Scheme of Amalgamation pursuant to SEBI regulations. It includes detailed disclosures pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which typically governs material events and corporate actions. The content includes information about the entities involved in the amalgamation, rationale, nature of consideration, and changes in shareholding pattern. There is no indication that this is a full financial report, audit report, or earnings release. Instead, it is an announcement of a corporate action (Scheme of Amalgamation) following regulatory requirements. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as amalgamations or mergers. The document length is about 4732 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is CAP with high confidence.
2019-12-07 English
Outcome of Board Meeting
M&A Activity Classification · 95% confidence The document is an official announcement dated December 7, 2019, addressed to stock exchanges (BSE and NSE) regarding the outcome of a Board Meeting. The subject is the intimation of a Scheme of Amalgamation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The content includes detailed disclosures about the amalgamation, such as entities involved, rationale, consideration, and changes in shareholding pattern. It is a regulatory announcement about a corporate restructuring transaction (amalgamation). The document is not a full financial report, audit report, or earnings release. It is not a proxy or voting result announcement. It is a formal disclosure of a corporate transaction to the stock exchanges as required by SEBI regulations. This fits best under the category of M&A Activity (Code: TAR), which covers announcements and documents related to merger proposals or takeover bids, including amalgamations.
2019-12-07 English
Board Meeting — Other business matters
Board/Management Information Classification · 95% confidence The document is a short communication addressed to the stock exchanges (NSE and BSE) regarding an intimation of a Board Meeting. The text includes phrases like 'Intimation of Board Meeting' and is directed to the Listing Department, which is typical for announcements about board meetings or management changes. The document length is only 668 characters, indicating it is a brief notice rather than a detailed report. There is no financial data, no detailed management discussion, no voting results, or other report content. Therefore, this document is best classified as Board/Management Information (MANG), which covers announcements of changes or meetings related to the company's board or senior management.
2019-12-03 English
Financial Result Updates
Regulatory Filings
2019-11-14 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is dated November 14, 2019, and is addressed to stock exchanges (BSE and NSE) with reference to the outcome of a board meeting. It announces the approval of un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2019, along with the limited review report and financial highlights. The document contains detailed financial data for the quarter and half year, including income, expenses, profit before tax, and tax expenses. This indicates it is a comprehensive interim financial report for a period shorter than a full fiscal year, containing substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length is 15,000 characters, which is substantial and not merely an announcement or certification. Hence, the classification is IR with high confidence. H1 2020
2019-11-14 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) informing about the scheduling of a Board Meeting to consider and approve the Un-Audited Standalone and Consolidated Financial Results for the quarter ended September 30, 2019. It also mentions the closure of the trading window for insiders as per SEBI regulations. The document is dated November 4, 2019, and is a notification of an upcoming event rather than the financial results themselves. The document length is 2539 characters, which is relatively short and consistent with an announcement rather than a full report. There is no actual financial data or detailed analysis included. Therefore, this document is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement informing the market about the Board Meeting and trading window closure, not the financial results report itself.
2019-11-04 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.